Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 222-852-4
CAS number: 3634-83-1
Short description of key information on bioaccumulation potential result: For risk assessment purposes the following absorption factors were derived: oral absorption factor: 50%; dermal absorption factor: 100%; inhalation absorption factor: 100%Short description of key information on absorption rate: A dermal absorption factor of 100% should be considered for risk assessment purposes.
As XDI is a diisocyanate, it reacts with water. Isocyanates
hydrolyze readily in water to yield a carbamic acid, which
decarboxylates to produce CO2 and an amine; the latter can immediately
react with more isocyanate to yield a disubstituted urea. The hydrolysis
rate increases with electron-withdrawing substituents. Steric hindrance
also influences hydrolysis rate. Even at low pH, a hydrolysis Half-Life
< 10 minutes (25°C) has been found for isocyanates. Physicalchemical
characteristics of XDI requiring studies in aqueous surroundings (as
water solubility, octanol/water partition coefficient and surface
tension) can therefore not be determined on XDI
itself. The short hydrolysis half-life indicates that the parent
compound may only be present in the GI-tract for a limited period of
time. Hence, toxicokinetic predictions based on the characteristics of
the parent compound may be of limited relevance. As human absorption of
a substance always requires contact with aqueous solutions, it is
concluded that any uptake of XDI will be very limited.
When considering the calculated values for water solubility and
partition coefficient as determined for the CSA, it is anticipated that
the relative small molecular size (<200) and the moderate log Pow
(between 0 and 4) of XDI are favourable for absorption, whereas the
relatively low water solubility (106.27 mg/L) is not favourable for
absorption by the GI-tract. Based on these physicochemical properties of
XDI, a moderate uptake by the GI-tract is anticipated, and for risk
assessment purposes the oral absorption of XDI is set at 50%. The
results of the toxicity studies do not provide reasons to deviate from
this proposed oral absorption percentage.
After absorption, XDI will react with water as stated above,
yielding carbamic acid, CO2, amine and disubstituted urea. Because of
the relative small molecular weight of XDI, the hydrolysis products
and/or metabolites will either be excreted via the bile or the urine.
Moderate log P values (between -1 and 4) are favourable for
absorption directly across the respiratory tract epithelium by passive
diffusion. The low vapour pressure of the substance (0.0206 Pa)
indicates that the substance will not be available for inhalation as
vapour. The relatively low water solubility is favourable for
penetration to the lower respiratory tract. Based on these
physico-chemical properties of XDI, for risk assessment purposes the
inhalation absorption is set at 100%. The results of the toxicity
studies do not provide reasons to deviate from this proposed inhalation
Discussion on absorption rate:
XDI, being a liquid, has the potential to be dermally absorbed. The
moderate log Pow of 3.07 is also indicative of dermal absorption. The
criteria for 10% dermal absorption as given in the Reach Guidance on
information requirements and chemical safety assessment (MW>500 and log
Pow is outside of the range -1 to 4) is not met, and therefore 100%
dermal absorption of XDI should be considered for risk assessment
purposes. Although it is generally accepted that dermal absorption is
not higher compared to oral absorption, 100% dermal absorption should be
considered for risk assessment purposes as XDI has skin irritating
properties and damage to the skin surface may enhance penetration.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Deze website maakt gebruik van cookies om het surfen zo aangenaam mogelijk te maken.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again